Ab1011 #ACR22 @SMerjanah: Fracture rates among vets with AS Increasing fx incidence for AS and comparator groups over time There was increase in fractures during TNFi era 2004-2021 compared to pre-TNFi, does not show fx sparing effect @RheumNow https://t.co/fTSYbFcxqo

Wiebe et al. Steroids <=5mg/day not associated negative effect on BMD. Of course steroid-related increase in fracture risk is not fully captured by BMD effect @RheumNow #ACR22 Abstr#1318 https://t.co/Ond5gzopRa https://t.co/HX2AUyQmsf

#ACR22 Abstr#1569 Lung complications are common in #VEXAS but what are the common radiologic findings? A cohort study in 22 men showed abnormalities were found in most patients but were non-specific. Most commonly parenchymal changes (73%) @RheumNow https://t.co/kjYSHON2yN

Pala et al. Increasing disease activity by CDAI associated increasing patient-reported cognitive dysfunction in RA. More pronounced in younger patients. @RheumNow #ACR22 Abstr#1397 https://t.co/eRFxe27qgq https://t.co/NUtTaAcrik

Meng et al. ESR/CRP and steroid associated increased risk of MACE in IA. NSAIDs/COX-2 and MTX associated reduced risk of MACE in IA. @RheumNow #ACR22 Abstr#1207 https://t.co/OvjNZkpWpy https://t.co/9NMIJPcV9G

Ab1486 #ACR22 @Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA Prediction base model w only traditional CV risks excellent (AUC 85.5) Expanded model w damaged jts did not improve risk discrimination @Rheumnow https://t.co/DMlOreW9zK

Spiera et al. Resolution PMR in SAPHYR trial IL-6i sarilumab. Week 52, 81% vs 57% with no signs/symptoms More in PBO arm needed rescue GCs 58.6% vs 32.2% @RheumNow #ACR22 Abstr#1543 https://t.co/3Sr8aB2SpC https://t.co/mjuzNFWcdn

Katz @GuyKatzMD et al. Coronary involvement in IgG4-RD. 13 cases, all male, median 11 years disease. All elevated serum IgG4. Aneurysms 8/13, arteritis 9/13 periarteritis 11/13. @RheumNow #ACR22 Abstr#1571 https://t.co/At7Gw2kRUp https://t.co/zcXc6oUS0f

Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk of lymphoma. IR 1.68/1000PY (95% CI 1.5-1.9) on csDMARD vs IR 1.73/1000PY (95%CI 1.4-2.1) on b/tsDMARD. @RheumNow #ACR22 Abstr#1210 https://t.co/3Uvz3mvsGM https://t.co/6k3Vqb21KF

Are preexisting autoimmune dx pts okay for PD-1i/CTLA-4i combo immunoRx (vs PD-1i single agent)? Common question in practice for your rheum pts who get cancer Combo ICI means: de novo irAE: double risk flares: same risk Give our pts what they need! ABST0757 #ACR22 @RheumNow https://t.co/Vs1AoM54Ut

Ab1508 #ACR22 Enthesitis on PET/CT 20 untreated PsA pts w/ total body PET/CT All 20 (100%) pts had entheseal inflammation 127/543 (~1/4) entheses showed inflammation @RheumNow https://t.co/OQCBWW70bt